El interés en corto de Alnylam Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Alnylam Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Bolsa, Informe de interés en corto

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

ALNYLAM PHARMACEUTICALS ORD

In the last three months, 24 analysts have published ratings on Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $322.83, a high estimate of $400.00, and a low estimate of $220.00. This current average has increased by 5.3% from the previous average price target of $306.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1730746808_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Alnylam Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$298.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$310.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$329.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$366.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$371.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$314.00</td>
<td>$307.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$307.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$248.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$198.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alnylam Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Alnylam Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Alnylam Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Alnylam Pharmaceuticals Better</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Alnylam Pharmaceuticals's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -33.26%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Alnylam Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -22.27%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -761.91%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.72%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 40.24, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ALNY

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (24 Ratings)

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

News

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Raymond James analyst Gary Nachman maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $275 to $298.

Raymond James Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $298

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and maintains $300 price target.

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target

Scotiabank analyst Greg Harrison maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Sector Outperform and raises the price target from $305 to $310.

Scotiabank Maintains Sector Outperform on Alnylam Pharmaceuticals, Raises Price Target to $310

Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Overweight and raises the price target from $295 to $329.

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $329

Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $366 to $384.

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $384

Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $300 price target.

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $300 Price Target

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $320 price target.

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has risen 7.43% since its last report. The company recently reported that it has 4.84 million shares sold short, which is 4.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730403932_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest

WIIM

Alnylam Pharmaceuticals shares are trading lower after the company reported mixed Q3 financial results.

2024 Financial Guidance
Full year 2024 financial guidance is reiterated and consists of the following:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,575 million - $1,650 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Product Revenue Growth vs. 2023 at reported FX rates1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">27% to 33%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Product Revenue Growth vs. 2023 at CER&#x2A;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">28% to 34%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net revenues from collaborations and royalties</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$575 million - $650 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP R&amp;D and SG&amp;A expenses</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2,000 million - $2,150 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP R&amp;D and SG&amp;A expenses2</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,775 million - $1,875 million</td>
</tr>
</tbody>
</table>
</figure>

Biotech

Earnings

Guidance

Health Care

General

Alnylam Pharmaceuticals Reiterated 2024 Financial Guidance, Including Combined Net Product Revenues Of $1.575B-$1.65B

Alnylam Pharmaceuticals Q3 2024 Adj EPS $(0.50) Beats $(0.93) Estimate, Sales $500.92M Miss $533.10M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54144398&amp;newsitemid=20241030248743&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=16bba99b98283f667e54fc60de517cad">Alnylam Pharmaceuticals, Inc. </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloidosis (ATTR) and hypertension programs at the upcoming American Heart Association (AHA) Scientific Sessions 2024, November 16–18, 2024.
Data presentations for the Company's flagship TTR franchise include new findings from an analysis of the HELIOS-B Phase 3 study of vutrisiran, an RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), as well as interim results from a Phase 1 study evaluating ALN-TTRsc04, a next generation RNAi therapeutic in development for the treatment of ATTR amyloidosis. Full results from the HELIOS-B study, the largest and most contemporary ATTR-CM study to date, were published in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nejm.org%2Fstoken%2Fdefault%2Bdomain%2FREPRINTS_36492%2Ffull%3FredirectUri%3D%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2409134&amp;esheet=54144398&amp;newsitemid=20241030248743&amp;lan=en-US&amp;anchor=The+New+England+Journal+of+Medicine&amp;index=2&amp;md5=ac1c0a496a73eb8c923c93e94528836d">The New England Journal of Medicine</a> earlier this year. The study achieved all 10 pre-specified primary and secondary endpoints. In addition, the Company will present a new analysis of the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension.

Alnylam To Showcase Latest Data From TTR Franchise And Hypertension Program At American Heart Association Scientific Sessions 2024

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.86% on an annualized basis producing an average annual return of 20.77%. Currently, Alnylam Pharmaceuticals has a market capitalization of $38.06 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,737.21 today based on a price of $296.48 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729711810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

TD Cowen analyst Ritu Baral maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $282 to $371.

TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $371

Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz.
The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eds#NASDAQ">EDS</a>) in patients aged seven years and older with narcolepsy.
The company&#39;s shares rose 5.1% on the news.&nbsp;
The stock fell 1.4% year to date compared with the <a href="https://www.zacks.com/stocks/industry-rank/industry/medical-biomedical-and-genetics-105">industry</a>&#39;s 0.7% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/97/81744.jpg?v=1324361988" style="height:245px; width:624px" /> 
Image Source: Zacks Investment Research
<h3>Label Expansion Of AVDL&#39;s Lumryz</h3>
Lumryz is a once-at-bedtime formulation extended-release sodium oxybate. It was first approved by the FDA on May 1, 2023, for the treatment of cataplexy or EDS in adult patients with narcolepsy.
Along with the approval, the FDA also granted seven years of orphan drug exclusivity to Lumryz for the treatment of cataplexy or EDS in adults with narcolepsy due to a finding of clinical superiority of Lumryz relative to currently available oxybate treatments.
Narcolepsy is a chronic neurological condition, wherein the brain&#39;s ability to regulate the sleep-wake cycle is impaired.
The latest FDA approval expands the drug&#39;s indication for younger narcolepsy patients.&nbsp; The drug was also granted orphan drug exclusivity in pediatric narcolepsy patients aged seven years and older through Oct. 16, 2031.
Pediatric patients (seven years and older) living with narcolepsy will now have the same opportunity that adult patients with narcolepsy have &mdash; to choose a once-nightly treatment option that does not disrupt sleep for a middle-of-the-night dose.
<h3>Lumryz Uptake Boosts AVDL</h3>
Avadel generated $41.5 million of net product revenues from the sales of Lumryz in the second quarter of 2024.
As of June 30, there were more than 1,900 patients on Lumryz compared to more than 1,400 as of March 31.
Pediatric patients currently represent approximately 5% of all oxybate-treated narcolepsy patients. Hence, the label expansion of the drug for this population should boost sales.
In addition, a phase III double-blind, placebo-controlled, randomized withdrawal, multicenter study is evaluating the efficacy and safety of Lumryz in idiopathic hypersomnia (IH).&nbsp; Enrollment is open to patients who are currently being treated with a twice-nightly oxybate and those not taking oxybates. The study, which is expected to enroll approximately 150 adults diagnosed with IH, includes an open-label extension portion.
<h3>AVDL&#39;s Rank &amp; Other Stocks To Consider</h3>
Avadel carries a Zacks Rank #3 (Hold) at present.&nbsp; Some other top-ranked stocks in the drug/biotech sector are Catalyst Pharmaceuticals CPRX, ANI Pharmaceuticals ANIP and
<a href="https://www.zacks.com/stock/news/2353213/avadel-obtains-fda-nod-for-label-expansion-of-narcolepsy-drug-lumryz?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2353213">To read this article on Zacks.com click here.</a>

Small Cap

ANIP

CPRX

Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz

One step closer to achieving public reimbursement of AMVUTTRA&#xAE; for hATTR patients in Canada
MISSISSAUGA, ON, Oct. 18, 2024 /CNW/ - Alnylam Canada ULC is pleased to announce that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of AMVUTTRA&#xAE; (vutrisiran injection), an RNAi therapeutic administered by quarterly subcutaneous injection, for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).1&nbsp;This comes following a positive recommendation from the Canadian Drug Agency (CDA) and the Institut national d'excellence en santé et services sociaux (INESSS), and signals the next step in the process where individual participating provinces and territories will start to list&nbsp;AMVUTTRA&#xAE; on their formularies.

Global

Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults

Alnylam Pharmaceuticals&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) announced that it has submitted a Type II Variation to the&nbsp;European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to the encouraging news.
Please note that Alnylam already markets vutrisiran in the EU under the brand name Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
The application seeking approval for vutrisiran to treat ATTR-CM is supported by positive&nbsp;results from ALNY&#39;s pivotal phase III HELIOS-B study, which met all primary and secondary endpoints across both the overall and monotherapy populations, each with statistical significance.
Year to date, shares of Alnylam have gained 57% against the industry&#39;s 1% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/81532.jpg?v=982164009" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
Per the data readout, vutrisiran reduced mortality and cardiovascular events while improving functional capacity (measured by the six-minute walk test), quality of life (using the Kansas City Cardiomyopathy Questionnaire), and heart failure symptoms and severity (via New York Heart Association class) in ATTR-CM patients.
Additionally, the safety profile of vutrisiran in the HELIOS-B study was consistent with its known profile for treating hATTR amyloidosis with polyneuropathy in adults. In the late-stage study, the rates of adverse events, including those leading to discontinuation, were similar between the vutrisiran and placebo groups.
<h2>Amvuttra &ndash; The Key Growth Driver for Alnylam</h2>
Please note that Alnylam also markets Amvuttra, the company&#39;s lead drug, in the United States for the treatment of adult patients with polyneuropathy of&nbsp;hATTR amyloidosis. The drug&#39;s sales contribute significantly to ALNY&#39;s top line. Amvuttra generated sales worth $425.4 million in the first half of 2024, up 82% year over year on a reported basis. The encouraging uptake of the drug is driven by new patients starting treatment as well as patients switching from Onpattro. Onpattro is approved in the United States and EU to treat hATTR amyloidosis in adults.
We remind the investors that a supplemental new drug application for vutrisiran, seeking its label expansion to treat ATTR-CM is also currently under review in the United States. If the regulatory applications in the EU and the United States are approved, Alnylam believes that vutrisiran has the potential to become the new standard of care for the treatment of ATTR-CM. This will expand the eligible patient population for the drug driving substantial growth for the company in the future.
Other marketed products include Givlaari for acute hepatic porphyria and Oxlumo injection for subcutaneous use for the treatment of primary hyperoxaluria type 1 to lower urinary and plasma oxalate levels in pediatric and adult patients.
Alnylam also markets a fifth drug, Leqvio (inclisiran), in collaboration with Novartis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NYSE">NVS</a>) to treat hypercholesterolemia in the EU. In the United States, it is approved to reduce low-density lipoprotein cholesterol (LDL-C) with two doses per year. Per the agreement, Alnylam has granted Novartis exclusive and worldwide rights to manufacture and commercialize RNAi therapeutics targeting PCSK9 for treating hypercholesterolemia and other human diseases, including Leqvio. Novartis has also received FDA approval to expand Leqvio&#39;s label to include earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.
<div class="chart_embed">
<h3>Alnylam Pharmaceuticals, Inc. Price and Consensus</h3>
<img alt="Alnylam Pharmaceuticals, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/cd/1729169675.png" style="height:310px; width:600px" title="" />
Alnylam Pharmaceuticals, Inc. price-consensus-chart | Alnylam Pharmaceuticals, Inc. Quote
</div>
<h2>ALNY&#39;s Zacks Rank and Other Stocks to Consider</h2>
Alnylam currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are&nbsp;ANI Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>) and Amicus Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fold#NASDAQ">FOLD</a>). While ANIP sports a Zacks Rank #1 (Strong Buy), FOLD carries a Zacks Rank #2 at present.
In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have moved up from $4.69 to $4.81. EPS estimates for 2025 have improved from $5.37 to $5.86, during the same period. Year to date, shares of ANIP have gained 8.2%.
ANI Pharmaceuticals&#39; earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Amicus&#39; 2024 EPS have remained constant at 20 cents. EPS estimates for 2025 have increased from 48 cents to 50 cents, during the same period. Year to date, shares of FOLD have lost 26%.
Amicus&#39; earnings beat estimates in three of the four trailing four quarters, missing the mark once, with the average surprise being 23.96%.
<a href="https://www.zacks.com/stock/news/2352442/alnylam-stock-up-on-cardiomyopathy-drug-regulatory-filing-in-the-eu?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2352442">To read this article on Zacks.com click here.</a>

Earnings Beats

Large Cap

Mid Cap

Markets

FOLD

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IQVIA Holdings (IQV – Research Report), Alphatec Hol...

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Alphatec Holdings (ATEC) and Alnylam Pharma (ALNY)

Wells Fargo analyst Tiago Fauth maintained a Hold rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of $275.00. Th...

Alnylam Pharma (ALNY) Receives a Hold from Wells Fargo

Barclays analyst Gena Wang raised the firm's price target on Alnylam (ALNY) to $329 from $295 and keeps an Overweight rating on the shares followin...

Alnylam price target raised to $329 from $295 at Barclays

U.S. drugmakers and biotechs rely on Chinese partners for manufacturing, research, and ingredients, but, with geopolitical tensions rising, compani...

U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report) and Insmed (INSM – Resear...

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY) and Insmed (INSM)

In a report released today, Leland Gershell from Oppenheimer maintained a Hold rating on Alnylam Pharma (ALNY – Research Report). The company's sha...

Alnylam Pharma (ALNY) Receives a Hold from Oppenheimer

Raymond James analyst Gary Nachman raised the firm's price target on Alnylam (ALNY) to $298 from $275 and keeps an Outperform rating on the shares....

Alnylam price target raised to $298 from $275 at Raymond James

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target o...

Alnylam Pharma (ALNY) Gets a Buy from Evercore ISI

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Equillium (EQ – Research Report), Quest Diagnostic...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Equillium (EQ), Quest Diagnostics (DGX) and Alnylam Pharma (ALNY)

ATEC

AZNCF

INSM

IONS

IVVD

KYMR

NTLA

REGN

Press Releases

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Alnylam to Webcast TTR Investor Day

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

Alnylam Canada Signs Letter of Intent from pan-Canadian Pharmaceutical Alliance for the Public Reimbursement of AMVUTTRA® For The Treatment Of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis In Adults

Comments

Alnylam Pharmaceuticals

Interés en corto

Alnylam Pharmaceuticals (NASDAQ:ALNY) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL